Epidermal growth factor cancer vaccine - Bioven
Alternative Names: BV NSCLC 001; BV NSCLC 002; BVN-NSCLC-002; Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine; Center of Molecular Immunology Epidermal Growth Factor Vaccine; CimaVax EGF; CIMAvax Epidermal Growth Factor Vaccine; CIMAvax IM; CIMAvax-EGF; EGF cancer vaccine; EGF-P64K cancer vaccine; EGF-PTI; hrEGF-rP64k-Montanide ISA 51 VG; Recombinant human EGF-P64K/montanide Vaccine; Recombinant human EGF-rP64K/montanide ISA 51 vaccine; rEGF-P64K/Montanide ISA 51 vaccine; SAI-EGFLatest Information Update: 04 Jan 2024
At a glance
- Originator Center of Molecular Immunology
- Developer Bioven; Center of Molecular Immunology; National Cancer Institute (USA); Roswell Park Cancer Institute
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Prostate cancer
- Discontinued Colorectal cancer; Gastric cancer
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Bulgaria (IM)
- 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Georgia (IM)
- 04 Jan 2024 No development reported - Phase-III for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Romania (IM)